Since then, inhibitors against the CTLA-4 and PD-1 immune checkpoints have revolutionized the treatment of not only melanoma, but also malignant tumors such as non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), and Hodgkin’s lymphoma. The gene discussed is CTLA4; the disease is renal cell carcinoma.